Startups
Medial EarlySign develops machine learning based decision support tools that expose the hidden layer of information in standard medical data. These new insights enable personal and outcome-based interpretation of medical data, yielding individualized predictions and treatment options for each patient, as well as early prediction of life-threatening conditions. Our cutting edge tools are designed to offer healthcare organizations a new way of looking at their data, empowering them with proactive, personalized and predictive care management capabilities.
Medial EarlySign built and refined a unique algorithmic platform designed to handle large medical data and billions of medical data elements. Our validated algo-medical platform creates thousands of parameters based on existing medical data, analyzing trends and interrelationships over time. This enables setting personalized risk levels for mass populations in moments, and identifying individuals who may require further intervention.
Our solutions go through rigorous clinical validation. The company is currently conducting clinical trials in 14 leading research institutions around the world totaling more than 5 million patients.
Medial EarlySign built and refined a unique algorithmic platform designed to handle large medical data and billions of medical data elements. Our validated algo-medical platform creates thousands of parameters based on existing medical data, analyzing trends and interrelationships over time. This enables setting personalized risk levels for mass populations in moments, and identifying individuals who may require further intervention.
Our solutions go through rigorous clinical validation. The company is currently conducting clinical trials in 14 leading research institutions around the world totaling more than 5 million patients.
Overview
Employees
11-50
Total raised
$30M
Founded date
2013
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 17, 2024 | Medial App secures $120,000 in funding led by FirstCheque VC | iStock Social media platform Medial App has raised $120,000 in a pre-seed funding round led by FirstCheque VC, with participation from angel investors including Nayan Jadeja, Rohitashwa Choudhary, Ankit Aggarwal and others. With a beta-stag... |
| Sep 13, 2021 | EarlySign Announces New Partnership with Roche Diagnostics to Commercialize AI Solution for Early Detection of Cancer | Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, announced the signing of a definitive partnership agreement with Roche Diagnostics International Ltd. The agreement calls for a multi-... |
| Jan 14, 2020 | EarlySign, Maccabi Healthcare Launches AI-Powered Flu Vaccination Campaign | – Medial EarlySign unveils the first clinical implementation of its AI-based solution to identify unvaccinated individuals at high-risk of developing serious flu-related complications. – Developed in collaboration with leading Israeli HMO M... |
| Jun 3, 2019 | What’s health tech’s evolving role in cancer treatment? Learn more at the CONVERGE conference in Philadelphia! | Through a mix of provocative conversations, interactive networking, and a showcase of the hottest startups, you’ll get actionable insight into how AI, big data, precision medicine and more are transforming cancer treatment. Among the highli... |
| May 30, 2019 | This Israeli startup aims to catch disease early with data not diagnostic tests | In Israel and the European Union, the company’s ColonFlag product produces a ColonScore to determine colorectal cancer risk in patients. In the U.S., on the other hand, a similar AI tool called LGI Flag aims to unearth lower GI disorders. G... |
| Jan 22, 2019 | SLUCare picks Medial EarlySign’s AI tool to flag patients at risk for lower GI disorders | SLUCare Physician Group, the academic medical practice of Saint Louis University, has announced a partnership with Medial EarlySign, a startup leveraging AI technology to predict which individuals are at risk for specific health conditions.... |
| Mar 7, 2018 | Term Sheet — Wednesday, March 7 | 5 Qs WITH A DEALMAKER Patricia Nakache, a general partner at Trinity Ventures, calls her path to venture capital “serendipitous.” In 1999, she had recently left McKinsey & Company to join a startup at the peak of the dot-com boom. Paid ... |
| Mar 7, 2018 | China Digest: Horizons backs Medial Earlysign; Soocare secures $16m Series B | Premium Hong Kong venture capital firm Horizons Ventures joined investors in the $30-million Series A funding round in Israel’s Medial Earlysign while smart toothbrush maker secured $16 million in Series B. Continue reading this story with ... |
| Mar 6, 2018 | Machine learning health tech company Medial Earlysign secures $30 million | Israeli health tech company Medial Earlysign has announced a $30 million funding round led by aMoon Fund, the venture firm from Check Point founder Marius Nacht. Horizons Ventures also contributed to the Series B round along with Medial Ear... |
Show more
Reviews 0
FAQ about Medial EarlySign
When was Medial EarlySign founded?
Medial EarlySign was founded in 2013.
How much funding has Medial EarlySign raised?
Medial EarlySign has raised $30M in total across 1 funding round.
What has the press written about Medial EarlySign?
Parsers VC has collected 16 articles mentioning Medial EarlySign, among them “Medial App secures $120,000 in funding led by FirstCheque VC” (Jan 17, 2024) and “EarlySign Announces New Partnership with Roche Diagnostics to Commercialize AI Solution for Early Detection of Cancer” (Sep 13, 2021).
Is Medial EarlySign still active?
Yes, Medial EarlySign is active; its latest activity on Parsers VC dates from Jan 18, 2024.